USFDA conducts cGMP audit at Cipla’s Indore formulations facility

17 Apr 2018 Evaluate

The US Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) audit at Cipla’s Indore formulations facility from April 2, 2018 till April 13, 2018. This was in the normal course of business. There were no data integrity and/or repeat observations.

The company believes the observations are unlikely to have any material adverse impact and it will submit the response within the stipulated timeframe.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.


Cipla Share Price

1434.60 -13.00 (-0.90%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×